Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin compared to Retagliptin or Henagliflozein in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone
Epistemonikos ID: 7195b1660e52d501d3522241f58dc8e9b516a3b8
First added on: May 08, 2024